Hisun Pharma Subsidiary Receives New Veterinary Drug Registration for Broad-Spectrum Antiparasitic Spot-On

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) announced today that its subsidiary, Zhejiang Hisun Animal Health Co., Ltd., has received a Class IV New Veterinary Drug Registration Certificate from China’s Ministry of Agriculture and Rural Affairs for Compound Fipronil + Praziquantel + Moxidectin Spot-On Solution.

Product Details

• Active ingredients: Fipronil (ectoparasiticide) + Praziquantel (cestocide) + Moxidectin (endoparasiticide)

• Target species: Cats (indoor/outdoor)

• Indications: Prevention and treatment of internal and external parasitic infections, including:

  • Fleas and ticks (adulticide + egg/larval control)

  • Heartworm disease (prevention)

  • Gastrointestinal nematodes (roundworms, hookworms, whipworms)

  • Ear mites and sarcoptic mange mites

• Dosage form: Topical spot-on solution (monthly application)

• Registration class: Class IV (new combination of existing approved active substances)

• Certificate number: (2026) New Veterinary Drug Certificate No. 90

Development & Manufacturing

The product was co-developed by three companies, including Hisun Animal Health and two unnamed partners. Hisun confirmed the product is ready for production and commercialization, pending final veterinary drug product approval number from regulatory authorities.bjnews+1

Strategic Significance

Hisun stated the approval advances its veterinary pharmaceutical strategic layout and enhances market competitiveness in the companion animal health segment. However, the company noted that short-term financial impact will be limited until the product receives final marketing authorization and achieves commercial scale.

Market Context

The product competes in China’s monthly cat spot-on antiparasitic market, dominated by:

• Bayer/Elanco Advantage Multi (imidacloprid + moxidectin)

• Boehringer Ingelheim Broadline (fipronil + (S)-methoprene + praziquantel + eprinomectin)

• Virbac Stronghold Plus (selamectin + sarolaner)

• Domestic alternatives: Ruidesheng (fipronil + moxidectin), Hailiaomiao (milbemycin oxime + praziquantel tablets)sina.com+1

The triple-combination (fipronil + praziquantel + moxidectin) offers broad-spectrum coverage in a single monthly application, addressing a key unmet need for cat owners seeking convenience and comprehensive parasite protection.

Next Steps

Hisun Animal Health will now:

1. Apply for veterinary drug product approval number (final marketing authorization)

2. Complete production line validation and GMP compliance checks

3. Initiate commercial launch (timeline: Q4 2026 or Q1 2027, pending approval)

4. Execute veterinary education and marketing campaigns targeting companion animal clinics and e-commerce channels

About Hisun Pharmaceutical:
Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) is a leading Chinese pharmaceutical company with diversified portfolios in human pharmaceuticals, veterinary medicines, and APIs. Hisun Animal Health is its dedicated companion animal and livestock health subsidiary.